Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the single-arm CARDINAL study in recently transfused patients with cold agglutinin disease (CAD). CADENZA was a 26-week r...

Descripción completa

Detalles Bibliográficos
Autores principales: Röth, Alexander, Berentsen, Sigbjørn, Barcellini, Wilma, D’Sa, Shirley, Jilma, Bernd, Michel, Marc, Weitz, Ilene C., Yamaguchi, Masaki, Nishimura, Jun-ichi, Vos, Josephine M. I., Storek, Michael, Wong, Nancy, Patel, Parija, Jiang, Xiaoyu, Vagge, Deepthi S., Wardęcki, Marek, Shafer, Frank, Lee, Michelle, Broome, Catherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437710/
https://www.ncbi.nlm.nih.gov/pubmed/35687757
http://dx.doi.org/10.1182/blood.2021014955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437710/
https://www.ncbi.nlm.nih.gov/pubmed/35687757
http://dx.doi.org/10.1182/blood.2021014955

Ejemplares similares